Protalix BioTherapeutics, Inc. (PLX)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Protalix BioTherapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | 2.97 | 3.14 | 2.92 | 3.04 | 1,148,588 |
| Nov 18, 2026 | 2.89 | 3.02 | 2.88 | 3.02 | 962,924 |
| Nov 17, 2026 | 3.01 | 3.08 | 2.86 | 2.88 | 896,040 |
| Nov 16, 2026 | 3.00 | 3.07 | 2.95 | 3.03 | 1,290,382 |
| Nov 13, 2026 | 2.94 | 3.05 | 2.85 | 3.05 | 1,588,436 |
| Nov 12, 2026 | 3.12 | 3.13 | 2.92 | 2.96 | 2,436,756 |
| Nov 11, 2026 | 2.86 | 3.14 | 2.78 | 3.13 | 3,092,811 |
| Nov 10, 2026 | 2.45 | 2.96 | 2.45 | 2.86 | 3,039,600 |
| Nov 9, 2026 | 2.53 | 2.57 | 2.50 | 2.57 | 792,061 |
| Nov 6, 2026 | 2.51 | 2.59 | 2.48 | 2.54 | 364,044 |
| Nov 5, 2026 | 2.67 | 2.68 | 2.48 | 2.51 | 916,909 |
| Nov 4, 2026 | 2.61 | 2.73 | 2.58 | 2.69 | 870,832 |
| Nov 3, 2026 | 2.57 | 2.61 | 2.52 | 2.61 | 289,039 |
| Nov 2, 2026 | 2.60 | 2.62 | 2.54 | 2.56 | 726,274 |
| Oct 30, 2026 | 2.60 | 2.63 | 2.56 | 2.59 | 249,288 |
| Oct 29, 2026 | 2.59 | 2.68 | 2.59 | 2.61 | 274,762 |
| Oct 28, 2026 | 2.51 | 2.62 | 2.47 | 2.59 | 596,661 |
| Oct 27, 2026 | 2.48 | 2.54 | 2.46 | 2.53 | 448,304 |
| Oct 26, 2026 | 2.55 | 2.55 | 2.46 | 2.48 | 416,271 |
| Oct 23, 2026 | 2.54 | 2.56 | 2.50 | 2.55 | 383,908 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Grant/Award | 17.0K | -- | Sep 3, 2026 | |
| Director | Grant/Award | 17.0K | -- | Sep 3, 2026 | |
| Director | Grant/Award | 8.5K | -- | Sep 3, 2026 | |
| Director | Grant/Award | 8.5K | -- | Sep 3, 2026 | |
| Director | Grant/Award | 17.0K | -- | Sep 3, 2026 | |
| Director | Grant/Award | 8.5K | -- | Sep 3, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 4.2M | 5.0% | 13F |
HOLD Alapkezelo Zrt. · may incl. warrants· filed Oct 2026 | 4.2M | 4.9% | 13G |
STATE STREET CORP | 1.2M | 1.4% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 997.1K | 1.2% | 13F |
RENAISSANCE TECHNOLOGIES LLC | 988.1K | 1.2% | 13F |
GOLDMAN SACHS GROUP INC | 889.4K | 1.1% | 13F |
NORTHERN TRUST CORP | 831.7K | 1.0% | 13F |
DIMENSIONAL FUND ADVISORS LP | 717.0K | 0.9% | 13F |
VANGUARD PORTFOLIO MANAGEMENT LLC | 557.2K | 0.7% | 13F |
Stratos Wealth Partners, LTD. | 400.0K | 0.5% | 13F |
Insiders
- Ben Zvi ShmuelDirector
- Forster EliotDirector
- Schwartz AharonDirector
- Bashan DrorPRESIDENT AND CEO
- Naos YaronSr. VP & COO
- Melincoff Gwen ADirector
- Elze ChristianDirector
- Boudes Pol FDirector
- Bar-Shalev AmosDirector
- Rubin EyalSr. VP and CFO
Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins.
The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease.
Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases.
The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.
based on 84.32M shares outstanding
30d Avg
984.36K
60d Avg
941.12K
90d Avg
889.61K
Signal8's dilution snapshot of PLX as of Sep 30, 2026 records an effective S-3 shelf registration (effective Aug 22, 2025) and an at-the-market sales agreement dated Feb 27, 2023, from SEC filings. Protalix BioTherapeutics, Inc. (NYSE: PLX) traded at $3.04 on Nov 19, 2026, up 0.50% from the previous close of $3.02. 52-week range: $1.65 to $3.19. The company is in the Healthcare sector (Biotechnology).